A5063850381- Testicular diseases and treatments
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Acute Lymphoblastic Leukemia research
- Cancer Diagnosis and Treatment
- Hematological disorders and diagnostics
- Melanoma and MAPK Pathways
- Childhood Cancer Survivors' Quality of Life
- Neutropenia and Cancer Infections
- Sexual Differentiation and Disorders
- Urologic and reproductive health conditions
- Biomedical Text Mining and Ontologies
- Electronic Health Records Systems
- Electrolyte and hormonal disorders
- CAR-T cell therapy research
- Clinical practice guidelines implementation
- Epilepsy research and treatment
- Vascular Tumors and Angiosarcomas
- Ion Transport and Channel Regulation
- Blood disorders and treatments
- Multiple and Secondary Primary Cancers
- Head and Neck Cancer Studies
- Adolescent and Pediatric Healthcare
Leeds Teaching Hospitals NHS Trust
2015-2025
St James's University Hospital
2014-2023
University of Leeds
2015-2017
Huddersfield Royal Infirmary
2009
Bradford Royal Infirmary
2007
Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation vital. The Trial Imaging and Surveillance Seminoma Testis (TRISST) assessed whether magnetic resonance images (MRIs) or a reduced scan schedule could be used without unacceptable increase advanced relapses.A phase III, noninferiority, factorial trial. Eligible participants had undergone orchiectomy...
Abstract Background α-Fetoprotein (AFP) is conventionally absent in testicular classical seminoma (TCS). However, moderate AFP elevations can occur TCS patients, as observed at this and other centres, which be challenging to diagnostic management practices. Methods This retrospective cohort study considered concentration the context of germ-cell tumour diagnosis characterisation baseline (BL), disease status during chemotherapy, long-term surveillance. The patients with histologically...
TPS653 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 is standard first-line chemotherapy for intermediate poor-risk metastatic GCT. Acceleration of regimens by shortening the cycle length to 2-weekly improved cure rates in other cancers. P3BEP first international, randomized trial GCT include adults children both sexes. It aims determine superiority accelerated BEP versus this setting. Methods: This open label, randomized, phase 3 conducted seamlessly 2 stages. The...
The use of the CTLA4 inhibitor, ipilimumab, has proven efficacious in treatment melanoma, renal carcinoma and non-small cell lung cancer; however, it is associated with frequent immune-related adverse events (irAE). Ipilimumab-induced hypophysitis (IIH) a well-recognised not infrequent endocrine irAE.To investigate timing onset severity adrenal thyroid hormone dysfunction around development IIH patients treated for melanoma.Aretrospective review levels consecutive adult ipilimumab (3 mg/kg)...
Use of point-of-care testing is increasing, however many haematology analysers can only determine granulocyte count without further differentiation into neutrophils, eosinophils and basophils. Since the diagnosis life-threatening neutropenia in cancer patients requires a distinct neutrophil count, this study aimed to comparative performance between count. A database 508 646 venous full blood results measured on laboratory reference analyser was mined from large oncology unit. The...
TPS524 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 remains standard first-line chemotherapy for intermediate poor-risk metastatic GCT. Accelerating regimens by shortening the cycle length to 2-weekly improved cure rates in other cancers. P3BEP is first international, randomized trial of GCT include adults children both sexes. It aims determine superiority accelerated BEP versus this setting. Methods: This open label, randomized, phase 3 conducted seamlessly 2...
Abstract Introduction Immune checkpoint inhibitors (ICIs) are immunomodulatory molecules that downregulate T-cell inhibiting-receptors or ligands to promote an enhanced anti-tumour response. Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4) has been shown significantly improve survival in patients with metastatic melanoma. Immune-related adverse events (irAEs) occur some increased activation, of which ipilimumab-related hypophysitis (IH)...
TPS431 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 remains standard 1st line chemotherapy for intermediate or poor risk metastatic GCT. Accelerating regimens by shortening the cycle length to 2-weekly improved cure rates in other cancers. P3BEP will determine effects of accelerated versus BEP this setting. This is a first international, randomized trial poor-risk GCT include adults children both sexes. Methods: open label, randomized, phase 3 conducted seamlessly...
TPS5102 Background: Bleomycin, etoposide, and cisplatin (BEP) given 3-weekly x 4 remains standard 1st line chemotherapy for intermediate or poor risk metastatic GCT. Accelerating regimens by shortening the cycle length to 2-weekly improved cure rates in other cancers. P3BEP will determine effects of accelerated versus BEP this setting. This is first international, randomized trial poor-risk GCT include adults children both sexes. Methods: open label, randomized, phase 3 conducted seamlessly...